alexa Palivizumab In Preventing Respiratory Syncytial Virus Outbreaks In Neonatal Intensive Care
ISSN: 1948-5964

Journal of Antivirals & Antiretrovirals
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

4th World Congress on Virology
October 06-08, 2014 Hilton San Antonio Airport, TX, USA

Hammoud M S
Accepted Abstracts: J Antivir Antiretrovir
DOI: 10.4172/1948-5964.S1.022
Background: Respiratory syncytial virus (RSV) causes frequent nosocomial outbreaks in general pediatric wards but is less commonly reported in neonatal intensive care units. We investigated an outbreak of RSV infection in the neonatal unit at Maternity Hospital and call for a review of theguidelines of palivizumab prophylaxis is suggested. Methods: Chart review was performed after an RSV outbreak which occurred in our unit in February 2012. A case of RSV was defined as an infant with a nasopharyngeal aspirate positive for RSV by PCR technique. Management of the infected infants and their outcome were also recorded. Results: During the outbreak, 12 preterm infants turned RSV positive (mean age at infection, 38days; mean birth weight, 1457 g; and mean gestational age, 31 weeks). Six infected infants became very sick and required intubation with mechanical ventilation. There was no significant difference in birth weight or gestational age between those who were intubated and the non-intubated infants. The RSV-positive patients were isolated, and infection control measures were implemented. Palivizumab was administered to all patients and their contacts and no new cases were subsequently identified. All infants survived Conclusion: The current guidelines which recommend palivizumabprophylaxisto preterm infants after discharge during winter season seem to be insufficient to prevent outbreaks in NCUs. Palivizumab combined with infection control measures appears to prevent the spread of RSV in the neonatal setting. More studies are needed to investigate whether the use of palivizumabprophylaxis should start at NCUs in order to reduce RSV outbreaks.
image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version